

Supplementary Table S1. List of Synergy Genes

Zfp503	Trpv4
Foxd2os	Pxdc1
Rps4l	Rgs10
Cyp2r1	Rpl39l
Tmem59l	Syde1
Tmem51	Sh2d4a
Gm53	Carns1
Slc22a3	BC016579
Crb3	Tceal1
Bend4	Slc16a11
Phactr2	2900026A02Rik
4933428G20Rik	Rinl
Id3	Dennd5b
Plxna1	Nrg1
Hivep3	Mtss1l
Lhcgr	Meg3
Sgsm3	Gm9199
Ppp1r3fos	Gramd2
5930403L14Rik	Myl10
BC048507	Itga2
Cacna1i	Tnfsf10
Obscn	Smtnl1
Gm3336	Sema3d
D430019H16Rik	Gstk1
Bgn	Myh10
Gata2	Vwc2
Epcam	Mapkapk3
Prkca	AI854703
Spry4	Selplg
Plod3	Igfals
Gfpt2	Slc17a8
Podxl	Ifi30
Vsig2	

Supplementary Table S2.

A, Statistical testing of DMCs identified in combination therapy compared to single treatment.

p-values (Wilcoxon)		Hyper-methylated DMCs		Hypo-methylated DMCs		All DMCs	
		AC220	AG-221	AC220	AG-221	AC220	AG-221
<i>Idh2 Flt3</i>	AC220+AG-221	5.00E-02	7.30E-05	5.80E-07	6.10E-02	1.55E-07	1.22E-03
		Hyper-methylated DMCs		Hypo-methylated DMCs		All DMCs	
		AC220	5-Aza	AC220	5-Aza	AC220	5-Aza
<i>Tet2 Flt3</i>	AC220+5-Aza	9.10E-01	6.20E-01	1.20E-13	1.60E-02	1.21E-11	1.13E-02

B, Differentially methylated CpGs in response to combination therapy.

AC220+AG-221
- 39618 synergistic hypo-methylated CpGs (of which 38015 or 95.9% are unique to the combo treatment)
- 18808 synergistic hyper-methylated CpGs (of which 18271 or 97.1% are unique to the combo treatment)
AC220+5-Aza
- 16572 synergistic hypo-methylated CpGs (of which 15477 or 93.4% are unique to the combo treatment)
- 7624 synergistic hyper-methylated CpGs (of which 7554 or 99.1% are unique to the combo treatment)